It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

GLP-1 inhibitors such as semaglutide and tirzepatide have become popular and effective for weight loss and blood sugar control. However, they’re not without side effects. Keep in mind the following to ...

Stablix Inc. has described new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Introduction: To design effective small molecule inhibitors targeting the immune checkpoint PD-1/PD-L1 and to explore their inhibitory activity. Methods: In this paper, a total of 69 PD-1/PD-L1 ...

The aim of this report is to present the results of conversion therapy with Gemcitabine plus S-1 (GS) combined with PD-1 inhibitors (Zimberelimab) in a 74-year-old female IIIB iCCA patient. After 6 ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.

The MOA, signed by Peter Dan P. Punongbayan, MM, School President, and JCSUPT CESAR M LANGAWIN, BJMP Regional Director, focuses on equipping PDL and personnel with essential computer skills, ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder cancer, positioning the Big Pharma to file for approval of ...

Experts say the kuranui, otherwise known as moa, played a vital part in sustaining rākau Māori, crucial to the wellbeing of the taiao and the Māori language. The kuranui, otherwise known as moa ...